Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic SyndromeGarrett W. Rhyasen, Daniel T. Starczynowski, Lesley Mathews et al.|Cancer Cell|2013Cited by 203
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1Jing Fang, Daniel T. Starczynowski, Garrett W. Rhyasen et al.|Blood|2012Cited by 103
Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletionEsther N. Oliva, Roberto Latagliata, Maria Cuzzola et al.|European Journal Of Haematology|2010Cited by 29